11 Hurley Steet
About Tango Therapeutics
Tango Therapeutics is a biotechnology company developing novel medicines for patients by discovering and drugging context-dependent vulnerabilities in cancers. Tango was launched in 2017 by Third Rock Ventures and is headquartered in Cambridge, Mass.
President and Board Chairman: Alexis Borisy
14 articles with Tango Therapeutics
Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies
Global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer.
The deal, which will last several years, has Tango performing target discovery and validation. Gilead will be able to option rights to up to five targets that come out of Tango’s work.
CEO of Tango Therapeutics and Venture Partner at Third Rock Ventures to lend her expertise to FogPharma as the Company continues to advance a powerful new class of medicines - cell-penetrating miniproteins - for the treatment of serious diseases
Tango Therapeutics today announced the appointment of Malte Peters, MD, to its board of directors.
Tango Therapeutics Bolsters Expertise in Oncology Translational Research and Clinical Pharmacology with Leadership Expansion
Alan Huang, Ph.D. appointed chief scientific officer
Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Com...
4/24/2018Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors.
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
Tango Therapeutics Expands Board of Directors with the Addition of Leading Oncology Experts with Deep Experience in Targeted and Personalized Therapies
Tango Therapeutics, a biotechnology company creating novel, targeted medicines for specific cancer subtypes, today announced the addition of three experienced leaders with deep backgrounds in personalized cancer research, drug discovery and development to the board of directors.
Tango officially launched in 2017 and hit the ground running as a cancer drug target discovery and drug development company based on CRISPR technology.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Narayan brings extensive leadership experience in business development, operations and legal operations within the biotechnology and pharmaceuticals industries, most recently through his role as Vice President and Head of Transactions at Johnson & Johnson (J&J) Innovation in Boston.